Cabozantinib versus everolimus in patients with advanced renal cell carcinoma from Europe and the rest of the world: subgroup analysis of the METEOR trial
By: M. Schmidinger, Vienna (AT)
Session: Oral presentation of the 6 best abstracts Oral presentation of the 6 best abstracts
Location: Saturday, 10 November 2018, 12:00 - 12:30, Auditorium